Drug Pricing
Commentary
Small-Molecule Price Controls Are A Big Mistake
The Biden administration is in the midst of setting the terms for its program of price controls on prescription drugs dispensed through Medicare. The first 10 medicines subject to the price caps will be selected by the end of this year. That prospect is already chilling investment in drug research, particularly ...
Drug Innovation
Wayne Winegarden on NTD News to Discuss Congress Pushing Back on Pharmaceutical Benefit Managers
Congress is beginning to push back on pharmaceutical benefit managers (PBMs). PRI’s Wayne Winegarden tells NTD News that a large problem lies in the lack of transparency in the drug pricing system. Reforming the PBM system could reduce costs for patients. Click to watch the interview on NTD News.
Commentary
Price controls in Medicare will kill new cures
President Biden just released his budget plan for the next fiscal year. It purports to extend Medicare’s solvency by decades and reassure the millions of Americans who rely on the program. But once they realize his approach will grind drug research to a halt, perhaps they’ll come to a different conclusion. The ...
Commentary
Read about the middlemen in healthcare
Pharmacy benefit managers are picking patients’ pockets
Pharmacy benefit managers are in the congressional hot seat. Last Thursday, the Senate Finance Committee held a hearing examining the middlemen’s impact on patients. Earlier in March, the House Committee on Oversight and Accountability launched an investigation into PBM tactics that are “harming patient care and increasing costs for consumers.” ...
Commentary
A Bipartisan Regulatory Reform Opportunity: 340B
Despite the rancor, there are many bipartisan opportunities for the divided 118th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug discount program. 340B enables qualifying institutions to purchase medicines from manufacturers at steep discounts, generally between 25% and 50% off list ...
Blog
Key Takeaways from President Biden’s Proposed 2024 Healthcare Budget
The United States currently faces a deficit of over $700 billion. Not including other health programs, in 2021, over $734 billion was spent on Medicaid alone. Despite these facts, President Biden’s 2024 budget proposal aims to increase funding for healthcare by 11.5%. The proposal claims proposed tax increases will not ...
Commentary
How The Republican House Can Prevent Medicare Price Controls From Becoming Death Sentences
The Inflation Reduction Act’s (IRA) drug pricing provisions will severely curtail life-science research. The IRA vests the Centers for Medicare & Medicaid Services with the power to impose price controls on an ever-expanding list of drugs. The direct result will be that seniors today — as well as future generations ...
Commentary
Diversifying America’s supply chains point to a more prosperous economic future
Rep. Cathy McMorris Rodgers, R-Wash., the chair of the powerful House Energy and Commerce Committee, recently warned that the United States is “dangerously dependent” on Chinese supply chains, especially for the raw materials used to make medicines. Her statement reflects the genuine worries of industry experts and ordinary Americans. If ...
Commentary
Democrats’ Price Controls Undermine Biden’s Cancer Moonshot
Last night’s State of the Union address was a festival of cognitive dissonance. President Biden proudly lauded the price controls that Democrats have begun implementing on prescription drugs as part of last August’s Inflation Reduction Act. He also touted his administration’s Cancer Moonshot, which aims to halve the cancer death rate ...
Commentary
Grave Mistake to Fix Drug Prices Without Esteem for Their Value
Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
Small-Molecule Price Controls Are A Big Mistake
The Biden administration is in the midst of setting the terms for its program of price controls on prescription drugs dispensed through Medicare. The first 10 medicines subject to the price caps will be selected by the end of this year. That prospect is already chilling investment in drug research, particularly ...
Wayne Winegarden on NTD News to Discuss Congress Pushing Back on Pharmaceutical Benefit Managers
Congress is beginning to push back on pharmaceutical benefit managers (PBMs). PRI’s Wayne Winegarden tells NTD News that a large problem lies in the lack of transparency in the drug pricing system. Reforming the PBM system could reduce costs for patients. Click to watch the interview on NTD News.
Price controls in Medicare will kill new cures
President Biden just released his budget plan for the next fiscal year. It purports to extend Medicare’s solvency by decades and reassure the millions of Americans who rely on the program. But once they realize his approach will grind drug research to a halt, perhaps they’ll come to a different conclusion. The ...
Read about the middlemen in healthcare
Pharmacy benefit managers are picking patients’ pockets
Pharmacy benefit managers are in the congressional hot seat. Last Thursday, the Senate Finance Committee held a hearing examining the middlemen’s impact on patients. Earlier in March, the House Committee on Oversight and Accountability launched an investigation into PBM tactics that are “harming patient care and increasing costs for consumers.” ...
A Bipartisan Regulatory Reform Opportunity: 340B
Despite the rancor, there are many bipartisan opportunities for the divided 118th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug discount program. 340B enables qualifying institutions to purchase medicines from manufacturers at steep discounts, generally between 25% and 50% off list ...
Key Takeaways from President Biden’s Proposed 2024 Healthcare Budget
The United States currently faces a deficit of over $700 billion. Not including other health programs, in 2021, over $734 billion was spent on Medicaid alone. Despite these facts, President Biden’s 2024 budget proposal aims to increase funding for healthcare by 11.5%. The proposal claims proposed tax increases will not ...
How The Republican House Can Prevent Medicare Price Controls From Becoming Death Sentences
The Inflation Reduction Act’s (IRA) drug pricing provisions will severely curtail life-science research. The IRA vests the Centers for Medicare & Medicaid Services with the power to impose price controls on an ever-expanding list of drugs. The direct result will be that seniors today — as well as future generations ...
Diversifying America’s supply chains point to a more prosperous economic future
Rep. Cathy McMorris Rodgers, R-Wash., the chair of the powerful House Energy and Commerce Committee, recently warned that the United States is “dangerously dependent” on Chinese supply chains, especially for the raw materials used to make medicines. Her statement reflects the genuine worries of industry experts and ordinary Americans. If ...
Democrats’ Price Controls Undermine Biden’s Cancer Moonshot
Last night’s State of the Union address was a festival of cognitive dissonance. President Biden proudly lauded the price controls that Democrats have begun implementing on prescription drugs as part of last August’s Inflation Reduction Act. He also touted his administration’s Cancer Moonshot, which aims to halve the cancer death rate ...
Grave Mistake to Fix Drug Prices Without Esteem for Their Value
Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
